The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...

After receiving a complete response letter last week, the other shoe has dropped for Atara Biotherapeutics and its pipeline ...

T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for ...

India's role in affordable cell and gene therapies, including CAR-T, and the need for a mission mode approach.

Umoja Biopharma has announced the closing of an oversubscribed $100m Series C financing round to progress CAR-T cell therapy pipeline.

CAR T cell therapy revolutionizes oncology by using engineered T cells to target and eliminate cancer cells, improving outcomes in hematological malignancies.

Novel Allogeneic Platform: CARGO’s novel allogeneic platform is a universal vector solution designed to limit immune-based rejection and enable durable response of CAR T-cell therapy. Through ...

According to a recent report from Future Market Insights, the global allogeneic T-cell therapies market was valued at USD 1.1 ...

In addition, Caribou highlighted successful execution across its three clinical-stage allogeneic CAR-T cell therapy programs in hematologic malignancies over the past year and provided an outlook on ...

THANK (Target to Hinder the Attack of NK cells)-uCAR® is CARsgen's proprietary technology to generate allogeneic CAR-T cells with improved expansion and persistence by modifying donor-derived T ...

KJ-C2219 is developed based on CARsgen's THANK-u Plus platform and is designed for the treatment of hematologic malignancies and autoimmune diseases. An investigator-initiated trial is ongoing in ...